ORIEL THERAPEUTICS
Oriel Therapeutics is a specialty pharmaceutical company developing and commercializing products to improve respiratory care. Combining an experienced product development team and a growing portfolio of innovative drug delivery technologies, Oriel is focused on delivering compelling patient options for the treatment of asthma and COPD.
ORIEL THERAPEUTICS
Industry:
Biotechnology Medical Device Pharmaceutical
Founded:
2001-01-01
Address:
Tarboro, North Carolina, United States
Country:
United States
Website Url:
http://www.orieltherapeutics.com
Total Employee:
11+
Status:
Closed
Contact:
919-313-1290
Email Addresses:
[email protected]
Total Funding:
26.5 M USD
Technology used in webpage:
SPF GoDaddy DNS SMTP.com
Current Employees Featured
Founder
Investors List
New Leaf Venture Partners
New Leaf Venture Partners investment in Venture Round - Oriel Therapeutics
Official Site Inspections
http://www.orieltherapeutics.com
Unable to get host informations!!!
More informations about "Oriel Therapeutics"
Oriel Therapeutics - Crunchbase Company Profile & Funding
Oriel Therapeutics is a specialty pharmaceutical company developing and commercializing products to improve respiratory care. Combining an experienced product development team …See details»
Oriel Therapeutics Company Profile 2024: Valuation, Investors ...
Information on acquisition, funding, cap tables, investors, and executives for Oriel Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Oriel Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Oriel Therapeutics, Inc. of Durham, NC. Get the latest business insights from Dun & Bradstreet.See details»
Oriel Therapeutics Inc - Company Profile and News
Company profile page for Oriel Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Oriel Therapeutics Company Profile | Management and ... - Datanyze
Oriel Therapeutics Profile and History . Based in Research Triangle Park, Oriel Therapeutics Inc. is an emerging inhaled drug delivery company based on innovative technology for aerosolizing …See details»
Oriel Therapeutics, Inc. - Drug pipelines, Patents, Clinical ... - Patsnap
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into …See details»
Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of ...
Apr 19, 2010 Novartis Investor Relations International: Susanne Schaffert Pierre-Michel Bringer John Gilardi Thomas Hungerbuehler Isabella Zinck Central phone: +41 61 324 7944See details»
NOVARTIS : Sandoz to acquire Oriel Therapeutics, gaining rights to ...
Apr 19, 2010 Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break …See details»
Oriel Therapeutics Inc. - VentureRadar
MEC Dynamics, based in San Francisco, California, is developing a ‘point of care’ device for testing HbA1c levels in diabetic patients. HbA1c is a key diagnostic marker of a...See details»
Sandoz To Take Over Oriel Therapeutics
Sandoz, a division of the Novartis group, has signed a definitive agreement to acquire Oriel Therapeutics, a US pharmaceuticals company, gaining exclusive rights to a portfolio of generic …See details»
Jim O'Neill (investor) - Wikipedia
Jim O'Neill is an American science and technology investor whom President-elect Donald Trump has selected to serve as United States Deputy Secretary of Health and Human Services, …See details»
Sandoz To Acquire Oriel Therapeutics - Chemical & Engineering …
Sandoz, the generic drug arm of Novartis, will purchase privately held Oriel Therapeutics for an undisclosed amount.North Carolina-based Oriel develops generics and drug delivery …See details»
Oriel Therapeutics - CB Insights
Apr 19, 2010 See Oriel Therapeutics funding rounds, investors, investments, exits and more. Evaluate their financials based on Oriel Therapeutics's post-money valuation and revenue.See details»
Novartis expands generics portfolio with Oriel buy
Apr 19, 2010 Novartis (NYSE: ADR) is beefing up its generic division Sandoz with the purchase of U.S.-based Oriel Therapeutics. The deal brings a pipeline of copycat respiratory meds, a …See details»
Sandoz to Acquire Oriel Therapeutics for Generic Respiratory Drugs
Apr 19, 2010 Sandoz says that the deal will give it three promising projects targeting leading drugs in the respiratory field. The company will also have access to Oriel’s FreePath™ drug …See details»
Sandoz To Acquire Oriel Therapeutics, Gaining Rights To Portfolio …
Sandoz has signed a definitive agreement to acquire Oriel Therapeutics, a privately held US pharmaceuticals company, gaining exclusive rights to a portfolio of generic drug candidates …See details»
Oriel Therapeutics Starts Testing Its Innovative Drug Delivery …
Apr 5, 2004 Vol. 17 •Issue 8 • Page 15Oriel Therapeutics Starts Testing Its Innovative Drug Delivery System By Vern Enge We’ve come a long way in health care since cavemen …See details»
Oriel Therapeutics - CB Insights
Oriel Therapeutics Management Team 4 Team Members. Oriel Therapeutics has 4 executives. Oriel Therapeutics's current Chief Executive Officer is Richard Fuller.See details»
Innovation Centers | Johnson & Johnson Innovation
Healthcare innovation wherever it originates.See details»
TORL BioTherapeutics - Crunchbase Company Profile & Funding
TORL BioTherapeutics announced that it has raised $158 million through an oversubscribed Series B-2 financing round. The funds will be used to advance the clinical development of its …See details»